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Background: Previous research suggests exposure to nicotine replacement therapy (NRT) may 
be associated with an increased risk of cardiovascular disease (CVD).
Methods: Using data from the United Kingdom’s Clinical Practice Research Datalink, this 
study aimed to evaluate CVD events and survival among individuals who attempted smoking 
cessation with the support of NRT compared with those aided by smoking cessation advice only. 
We studied CVD outcomes over 4 and 52 weeks in 50,214 smokers attempting to quit – 33,476 
supported by smoking cessation advice and 16,738 with the support of NRT prescribed by their 
primary care physician. Patients were matched (2 smoking cessation advice patients:1 NRT 
patient) on demographic and clinical characteristics during a baseline year preceding their quit 
attempt. Cox proportional hazard regression, conditional negative binomial regression model, 
and conditional logistic regression were used to analyze data.
Results: Mean (standard deviation) population age was 47 (11.2) years; 51% were females. 
Time to first diagnosis of ischemic heart disease (IHD) among NRT and smoking cessation 
advice patients was similar within the first 4 weeks, but shorter for NRT patients over 52 weeks 
(hazard ratio [HR]: 1.35, 95% confidence interval [CI]: 1.03–1.77). A similar trend was observed 
for cerebrovascular disease (HR: 1.54, 95% CI: 1.08–2.19). NRT patients with a prior diagnosis 
of IHD or cerebrovascular disease had a higher rate of primary or secondary care consultations 
for IHD or cerebrovascular disease by 52 weeks (rate ratio: 1.50, 95% CI: 1.14–1.99). Patients 
prescribed NRT had a shorter survival time over 52 weeks, compared with those receiving advice 
only (HR: 1.39, 95% CI: 1.09–1.76).
Conclusion: Our findings suggest that treatment with NRT over 4 weeks does not appear to have 
an impact on cardiovascular risks. However, a longer follow-up period of 52 weeks resulted in 
an increase in cardiovascular events for patients prescribed NRT, compared with those receiving 
smoking cessation advice only.
ENCePP registration ENCePP/SDPP/4238
Keywords: smokers, cardiovascular, risk, nicotine replacement therapy, smoking cessation 
advice
Background
Tobacco smoking is the second leading risk factor for disease globally,1 killing approxi-
mately six million people each year.2 The World Health Organization European Region 
has one of the highest proportions of deaths caused by tobacco in the world.3 In the 
United Kingdom (UK), statistics from 2013 estimated that smoking caused around 
80,000 deaths in adults aged >35 years, accounting for 17% of all deaths.4
Given the substantial harm caused by smoking, public health policies have focused 
on tobacco control measures.2 There have been large reductions in the prevalence of 
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smoking on a global scale; however, owing to population 
growth the number of smokers has increased.5 According to 
the World Health Organization , 21% of the global population 
aged ≥15 years smoked tobacco in 2012,6 amounting to 1.1 
billion smokers in the world, more than at any time in his-
tory.7 In the UK, figures from 2014 reported that one in six 
adults were smokers, about 10 million, of whom 22% were 
males and 17% females.8
Guidelines in the UK recommend that all smokers have 
their smoking status recorded at every medical consulta-
tion and are offered smoking cessation advice.9 The aim of 
nicotine replacement therapy (NRT) is to reduce both the 
motivation to smoke and withdrawal symptoms, by temporar-
ily replacing the nicotine from cigarettes, thereby facilitating 
the transition from cigarettes toward abstinence.10 Evidence 
supports the effectiveness of NRT for smoking cessation, 
and many guidelines recommend it as a first-line treatment 
for people seeking pharmacological treatment.10–12 In 2011, 
NRT was the most common smoking cessation intervention 
“prescribed” in England.13
The literature reports conflicting results as to the safety of 
NRT among high-risk patients. Anecdotal evidence has high-
lighted the incidence of cardiovascular events in patients with 
unstable coronary syndromes.14–17 Conversely, a randomized 
controlled trial (RCT) conducted by Joseph et al,18 found no 
significant increase in cardiovascular events in two high-risk 
groups with cardiovascular disease (CVD) when NRT patch 
users were compared with placebo patch users. A systematic 
review and meta-analysis of adverse events associated with 
NRT, including 92 RCTs and 28 observational studies, con-
cluded that the use of NRT was associated with a variety of 
side effects, including chest pain and heart palpitations.19 A 
more recent meta-analysis of RCTs reported an elevated risk 
of less serious cardiovascular events with NRT, but concluded 
that there was no clear evidence of harm with NRT.20
Evidence on the relationship between NRT and car-
diovascular events is largely derived from RCTs, which 
frequently have strict eligibility criteria and a tendency to 
exclude patients at high risk of vascular events and vascular 
comorbidities. Evidence from observational studies is more 
limited, but one study involving 33,247 patients prescribed 
NRT, concluded that the use of NRT was not associated with 
an increase in the risk of myocardial infarction (MI), stroke, 
or death when used in a real-world routine care setting.21
Further real-world effectiveness studies are needed to 
assess the safety profile of NRT in patients with, or at high 
risk of, CVD. We hypothesized that patients exposed to NRT 
(NRT patients) are at a higher risk of CVD compared with 
patients receiving smoking cessation advice only (smoking 
cessation advice patients).
The aim of this study was to compare CVD events, at 4 and 
52 weeks respectively, in NRT patients (individuals attempting 
smoking cessation with the aid of NRT as any, or a combina-
tion of, nasal spray, transdermal patches, inhaler or gum and 
tablets) compared with those in smoking cessation advice 
patients, in a representative UK primary care population.
Methods
Study design and data source
This historical, matched cohort database study comprised a 
1-year baseline characterization period and a 1-year outcome 
evaluation period on either side of an index date. The index 
date was defined as the time at which patients received either 
smoking cessation advice only or a first prescription of NRT.
Data were extracted from the Clinical Practice Research 
Datalink (CPRD), the world’s largest validated computer-
ized database of anonymized longitudinal medical records 
for primary care.22,23 At the time of this study, the CPRD 
comprised of ~10.6 million patients from >590 primary 
care practices throughout the UK. Records are derived from 
a widely used general practice software system and contain 
prescribing and coded diagnostic and clinical information 
as well as information on tests requested, laboratory results, 
smoking cessation advice recorded by general practitioners 
(GPs) using specific Read codes,24 and referrals made at or 
following on from each consultation.25
The study protocol was developed in collaboration with 
an independent steering committee and approved by the 
CPRD’s Independent Scientific Advisory Committee (proto-
col number 09_096R) prior to data extraction. The study pro-
tocol was publicly registered with the European Network of 
Centers for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP; registration number ENCePP/SDPP/4238). The 
study period ran from January 2000 to the end of December 
2009. Patient consent was not required due to the retrospec-
tive nature of this study.
Characteristics of participants
Eligible patients were current smokers during the baseline 
year, aged 18−75 years, who sought smoking cessation advice 
from their GP and had at least 1 year of up-to-standard data 
(as defined by the CPRD) prior to and following their quit date 
(ie, index date) or up to the time of death if death occurred 
within the outcome period. The outcome period is defined as 
up to 4 and/or 52 weeks post index date. End of observation 
occurred at the practice last collection date, patient transfer 
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out date, outcome diagnosis date, end of the study period (4 
and/or 52 weeks), or the study end date.
Patients were excluded if they were exposed to NRT or 
any other pharmacological smoking cessation interventions 
during the year preceding the index date. Patients in the smok-
ing cessation advice group, who received NRT or any other 
pharmacological smoking cessation interventions during the 
outcome period, were excluded, as were patients in the NRT 
group who switched to other (non-NRT) pharmacological 
smoking cessation interventions during the outcome period. 
Switching between different NRT products, or use of multiple 
NRT products, was permitted.
Patients in the NRT group received a first prescription for 
NRT as any, or a combination of, transdermal patches, nasal 
spray, gum, tablets, or inhaler at the index date. Patients who 
formed the group undertaking smoking cessation unaided by 
pharmacological interventions, only received smoking ces-
sation advice. This group was defined to reflect, as closely 
as possible, the patients in the exposed group, with the main 
exception of note being the decision by their physician to 
provide smoking cessation advice/education only, rather than 
a pharmacological intervention, at the index date.
Study end points
The co-primary end points were 1) time to diagnosis of 
ischemic heart disease (IHD) and 2) time to diagnosis of 
cerebrovascular disease over a 4-week outcome period 
(immediately post index date). These were also evaluated over 
a secondary 52-week outcome period. The 4-week outcome 
period allowed us to observe any immediate cardiovascular 
events. The 52-week outcome period allowed us to assess 
cardiovascular events and mortality over a longer time period; 
furthermore, it gave us the opportunity to detect any seasonal 
variations in the prevalence of cardiovascular events.
Additional secondary end points included the number 
of consultations for IHD or cerebrovascular disease (GP 
consultations, inpatient admissions, and emergency depart-
ment and outpatient attendances) and survival time (all-cause 
mortality, IHD-related death, cerebrovascular disease-related 
death) during the 4-week and 52-week outcome periods. By 
investigating the number of consultations, we hoped to cap-
ture not only new diagnoses, but also a picture of the level of 
health care resource utilization, such as reviews, monitoring, 
and acute events, as existing disease potentially worsened. 
A consultation was taken as a date in the consultation table 
that was not inpatient, outpatient, or emergency department 
visit. Specific consultation types were identified based on 
diagnostic (Read codes) entered on the date corresponding 
with a code list for IHD/cerebrovascular disease. Death dates 
were identified using Read-coded statement of deaths. The 
cause was inferred on the basis of Read codes recorded within 
a 7-day window of that event. The start of follow-up for end 
points of interest occurred from the index date of prescribed 
NRT and the smoking cessation advice date, respectively. 
The “time to” analyses assessment ran until the earliest of 
the specific outcome of interest or end of the outcome period.
Statistical analysis
To control potential confounding between comparator 
groups, patients in the smoking cessation advice group were 
matched to those in the NRT group on a 2:1 ratio based on 
sex, age (±5 years), hypertension diagnosis (on or at any time 
before the index date), CVD diagnosis (on or at any time 
before the index date), cerebrovascular disease diagnosis (on 
or at any time before the index date), IHD diagnosis (on or at 
any time before the index date), diabetes diagnosis ever (at 
any time in the records), and chronic obstructive pulmonary 
disease (COPD) diagnosis ever. Further information on the 
potential confounders evaluated in the study is available in 
the supplementary material.
Two-way comparisons between treatment groups using 
the reduced but matched datasets were carried out making 
minimal adjustments for other baseline confounders as 
necessary.
The proportion of patients with IHD/cerebrovascular 
disease diagnosis, proportion of deaths (all-cause mortality), 
and the number of primary and secondary care consultations 
due to IHD/cerebrovascular disease were compared using 
conditional logistic regression.
The time to diagnosis of IHD was analyzed using Cox 
proportional hazards model, with times censored at 4 or 52 
weeks. Patients with a prior diagnosis of IHD were excluded 
from this analysis. The same method was used to analyze the 
time to diagnosis of cerebrovascular disease, but patients with 
a prior diagnosis of cerebrovascular disease were excluded 
from the analysis.
The total number of consultations for IHD or cerebrovas-
cular disease during the 4- and 52-week outcome periods was 
investigated using a conditional negative binomial regression 
model (rate ratios) to obtain estimates of consultation/hos-
pitalization rates relative to the control group. Where counts 
were low, a conditional logistic regression model (odds ratios) 
was used, with the outcome categorized as none versus any 
consultations. Patients with a prior IHD and/or cerebrovas-
cular disease diagnosis were analyzed separately from those 
with no prior diagnosis of IHD or cerebrovascular disease.
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All survival times, until death due to IHD, cerebrovascular 
disease, or any cause, were analyzed using Cox proportional 
hazards regression (hazard ratios) with time censored at 4 or 
52 weeks. Proportional hazards were checked and met. All 
hazard ratios, odds ratios, and rate ratios were presented as 
NRT relative to cessation advice only. Read code lists were 
generated in conjunction with medical expert advice.
All analyses were carried out using IBM Statistical Pack-
age for the Social Sciences (SPSS) Statistics version 21 (IBM 
SPSS Statistics, Feltham, Middlesex, UK), Statistical Analysis 
System version 9.3 (SAS Institute, Marlow, Buckinghamshire, 
UK), and Microsoft Office Excel 2007 (Microsoft Corp., Red-
mond, WA, USA). Statistical significance was set at P<0.05.
Results
The unmatched cohort consisted of 57,920 patients, of whom 
40,799 received smoking cessation advice, and 17,121 were 
prescribed NRT. The mean (standard deviation [SD]) age was 
48 (11.5) years; 48% were female (Figure S1). After match-
ing for sex, age (±5 years), hypertension diagnosis, CVD 
diagnosis, cerebrovascular disease diagnosis, IHD diagnosis, 
diabetes diagnosis, and COPD diagnosis, there were a total 
of 50,214 patients (Figure S2) – 33,476 received smoking 
cessation advice only; 16,738 received their first prescription 
of NRT. The mean (SD) age of the matched cohort was 47 
(11.2) years; 51% were female (Tables 1 and 2).
At 4 weeks post index smoking cessation attempt, there 
was no difference between NRT patients and smoking cessa-
tion advice patients in terms of the primary outcomes of time 
to first IHD (unadjusted hazard ratio [HR] 95% confidence 
interval [CI]: 1.08 [0.56–2.06]) and cerebrovascular disease 
diagnosis (unadjusted HR [95% CI]: 1.00 [0.34–2.93]) or 
the secondary outcomes survival time and odds of primary 
and secondary care consultations for IHD or cerebrovascular 
disease (Table 3).
By week 52, the adjusted HR (95% CI) for time to first 
diagnosis of IHD was higher for NRT patients compared 
with smoking cessation advice patients: 1.35 (1.03–1.77). 
Compared with smoking cessation advice patients, at 
52 weeks there was also a shorter time to first diagnosis 
of cerebrovascular disease in NRT patients (unadjusted 
HR [95% CI]: 1.54 [1.08–2.19], Table 3; Figure 1) and 
survival time (adjusted HR [95% CI]: 1.39 [1.09–1.76], 
Figure 1). Cerebrovascular disease-related mortality and 
IHD remained low for both groups throughout the 52-week 
secondary outcome period. Among patients with a prior 
Table 1 Baseline demographic characteristics for the unmatched and matched cohorts
Characteristic 
Unmatched cohort Matched cohort
Advice (n=40,799) NRT (n=17,121) Advice (n=33,476) NRT (n=16,738)
Female sex 18,776 (46.0) 8,847 (51.7) 17,140 (51.2) 8,570 (51.2)
Age at index date, mean (SD) 47.9 (11.6) 46.8 (11.3) 46.8 (11.2) 46.8 (11.2)
BMI categorized
Underweight 854 (2.4) 407 (2.7) 735 (2.5) 384 (2.6)
Normal 14,456 (40.8) 6,321 (41.5) 12,107 (41.5) 6,191 (41.6)
Overweight 12,169 (34.3) 5,135 (33.7) 9,854 (33.8) 5,021 (33.7)
Obese 7,989 (22.5) 3,373 (22.1) 6,464 (22.2) 3,290 (22.1)
Year of index date, categorized
2006 18,005 (44.1) 10,136 (59.2) 14,811 (44.2) 9,864 (58.9)
2007 13,788 (33.8) 4,901 (28.6) 11,269 (33.7) 4,819 (28.8)
2008 9,006 (22.1) 2,084 (12.2) 7,396 (22.1) 2,055 (12.3)
COPD 1,804 (4.4) 898 (5.2) 1,604 (4.8) 802 (4.8)
Diabetes 2,754 (6.8) 1,012 (5.9) 1,910 (5.7) 955 (5.7)
CVD 2,750 (6.7) 1,361 (7.9) 2,354 (7) 1,177 (7)
IHD 767 (1.9) 401 (2.3) 636 (1.9) 318 (1.9)
Cerebrovascular disease 540 (1.3) 296 (1.7) 428 (1.3) 214 (1.3)
Angina 366 (0.9) 151 (0.9) 299 (0.9) 113 (0.7)
Hypertension 5,029 (12.3) 1,708 (10) 3,220 (9.6) 1,610 (9.6)
MI 240 (0.6) 194 (1.1) 213 (0.6) 154 (0.9)
CCI score, categorized
0 38,231 (93.7) 15,936 (93.1) 31,521 (94.2) 15,636 (93.4)
1–4 1,870 (4.6) 618 (3.6) 1,432 (4.3) 593 (3.5)
>5 698 (1.7) 567 (3.3) 523 (1.6) 509 (3.0)
Notes: Data are presented as n (%), unless otherwise indicated. BMI classification: underweight, ≤18.5; normal, 18.5–24.9; overweight, 25.0–29.9; obese, ≥30.0. COPD and 
diabetes are Read code diagnosis at any time; CVD, IHD, cerebrovascular disease, angina, hypertension and myocardial infarction are Read code for diagnosis at any time 
prior to, and including index date.
Abbreviations:  advice, smoking cessation advice; NRT, nicotine replacement therapy; CVD, cardiovascular disease; IHD, ischemic heart disease; MI, myocardial infarction; 
CCI, Charlson comorbidity index; SD, standard deviation; BMI, body mass index.
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diagnosis of IHD or cerebrovascular disease, those on NRT 
therapy had a higher rate of primary or secondary care 
consultations for IHD or cerebrovascular disease over 52 
weeks (adjusted rate ratio [RR]: 1.50, 95% CI: 1.14–1.99) 
compared with those receiving smoking cessation advice 
(Figure 1).
Table 2 Baseline primary and secondary care consultations and drug therapies for unmatched and matched cohorts
Characteristic Advice (n=40,799) NRT (n=17,121) Advice (n=33,476) NRT (n=16,738)
Total GP consultations, categorized
≤2 15,320 (37.5) 4,832 (28.2) 12,310 (36.8) 4,779 (28.6)
3–5 11,897 (29.2) 5,134 (30.0) 9,953 (29.7) 5,037 (30.1)
6–10 8,456 (20.7) 4,315 (25.2) 6,973 (20.8) 4,189 (25.0)
≥11 5,126 (12.6) 2,840 (16.6) 4,240 (12.7) 2,733 (16.3)
GP consultations for IHD 230 (0.6) 134 (0.8) 189 (0.6) 109 (0.7)
GP consultations for cerebrovascular disease 124 (0.3) 74 (0.4) 90 (0.3) 56 (0.3)
Outpatient department attendance for IHD n/aa n/aa n/aa n/aa
Outpatient department attendance for 
cerebrovascular disease
7(1.7b) n/aa n/aa n/aa
Inpatient admissions for IHD 6 (1.5b) n/aa n/aa n/aa
Inpatient admissions for cerebrovascular 
disease
7 (1.7b) n/aa 6 (1.5b) n/aa
Emergency department attendance for IHD n/aa n/aa n/aa n/aa
Emergency department attendance for 
cerebrovascular disease
n/aa n/aa n/aa n/aa
Diuretics 2,469 (6.1) 1,034 (6) 1,709 (5.1) 974 (5.8)
Antiarrhythmic drugs 886 (2.1) 421 (2.5) 724 (2.2) 406 (2.4)
β-adrenoceptor blocking drugs 1,904 (4.7) 808 (4.7) 1,419 (4.2) 753 (4.5)
Drugs for hypertension/heart failure 3,413 (8.4) 1,311 (7.7) 2,318 (6.9) 1,223 (7.3)
Nitrates, calcium-channel blockers, and other 
antianginal drugs
2,103 (5.2) 914 (5.3) 1,458 (4.4) 837 (5.0)
Antiplatelet drugs 1,912 (4.7) 978 (5.7) 1,405 (4.2) 862 (5.1)
Lipid-regulating drugs 3,171 (7.8) 1,416 (8.3) 2,273 (6.8) 1,304 (7.8)
Notes: Data are presented as n (%). Consultations and drugs are identified 1 year prior to, and including, index date. aData suppressed in accordance with CPRD policy 
owing to low numbers. bRepresent numbers 10–4.
Abbreviations: advice, smoking cessation advice; NRT, nicotine replacement therapy; IHD, ischemic heart disease; GP, general practitioner; CPRD, Clinical Practice 
Research Datalink; n/a, not applicable.
Table 3 Outcome results at 4 and 52 weeks for the matched cohort
Characteristic 4 weeks 52 weeks
Advice (n=33,476) NRT (n=16,738) Advice (n=33,476) NRT (n=16,738)
IHD diagnosis 26 (0.1) 14 (0.1) 134 (0.4) 92 (0.6)
Cerebrovascular disease diagnosis 10 (3a) 5 (3a) 71 (0.2) 55 (0.3)
Total primary and secondary care consultations for 
IHD or cerebrovascular disease, for patients with no 
prior diagnosis
0 32,419 (99.9) 16,208 (99.9) 32,298 (99.6) 16,130 (99.4)
1 21 (0.1) 9 (0.1) 100 (0.3) 59 (0.4)
≥2 n/ab n/ab 44 (0.1) 32 (0.2)
Total primary and secondary care consultations for 
IHD or cerebrovascular disease, for patients with prior 
diagnosis
0 1,002 (96.9) 491 (95.0) 866 (83.7) 404 (78.1)
1 26 (2.5) 23 (4.4) 134 (13.0) 73 (14.1)
≥2 6 (0.6) n/ab 34 (3.3) 40 (7.7)
IHD-related death n/ab n/ab 7 (4a) n/ab
Cerebrovascular disease-related death n/ab n/ab n/ab n/ab
Deaths (all-causes) 20 (0.1) 7 (4a) 177 (0.5) 143 (0.9)
Notes: Data are presented as n (%). IHD diagnosis analysis excludes patients with a prior IHD diagnosis; cerebrovascular disease diagnosis analysis excludes patients with a 
prior cerebrovascular disease diagnosis. aRepresent numbers 10–4. bData suppressed in accordance with CPRD policy due to low numbers.
Abbreviations: advice, smoking cessation advice; NRT, nicotine replacement therapy; IHD, ischemic heart disease; CPRD, Clinical Practice Research Datalink; n/a, not 
applicable.
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Discussion
This study of a real-world population found no significant 
differences in the primary end points of time to first IHD 
and cerebrovascular disease diagnosis at 4 weeks between 
patients attempting to give up smoking with the assistance 
of prescribed NRT or via smoking cessation advice alone. 
However, prescription of NRT to assist smoking cessation 
(compared with smoking cessation advice) was associated 
with a higher risk of IHD and cerebrovascular disease after 
1 year, perhaps owing to cumulative exposure. Moreover, 
patients prescribed NRT to aid their quit attempt had a higher 
mortality in the following year than those patients supported 
with smoking cessation advice only. Furthermore, we found 
an increased rate of primary and secondary care consultations 
for IHD and cerebrovascular disease for patients receiving 
NRT when a prior diagnosis of IHD or cerebrovascular 
disease was made.
Our results of increased IHD and cerebrovascular diagno-
ses by week 52 for patients taking NRT (HR: 1.35, 95% CI: 
1.03–1.77), and low instances of cardiovascular death, broadly 
support a recent meta-analysis.20 They reported an elevated 
risk of cardiovascular events with NRT that was driven by less 
serious events such as tachycardia, but concluded that NRT did 
not appear to be associated with more serious cardiovascular 
events. A study using the The Health Improvement Network 
(THIN) general practice database, included 33,247 patients 
taking NRT, and investigated acute MI, acute stroke, and death 
for each patient during exposed and unexposed time periods. 
The authors reported that although the incidence increased 
before exposure and decreased after exposure to NRT in the 
period of 56 days before and after first NRT prescription, NRT 
was not associated with an increase in risk of MI, stroke, or 
death.21 This is in agreement with our data that during short 
periods of evaluation of 4 weeks, there is no difference in 
cardiovascular incidence after exposure to NRT. However, 
our study examined the long-term effects of NRT and found a 
higher risk of IHD and cerebrovascular disease. Nevertheless, 
GP practices may contribute patient data to both CPRD and 
THIN, resulting in overlap of some patients between databases. 
Information about which practices contribute to either database 
is not publicly available; therefore, specific methods to identify 
overlap need to be applied to the data to exclude these patients.
Furthermore, Hubbard et al21 used a within-patient com-
parison, which could account for the differences observed 
IHD diagnosis
Cerebrovascular disease diagnosis
Consultations (no prior diagnosis)
Consultations (prior diagnosis)
All-cause mortality
IHD diagnosis
Cerebrovascular disease diagnosis
Consultations (no prior diagnosis)
Consultations (prior diagnosis)
All-cause mortality
4 weeks
Advice=1
Higher with NRT
OR/RR/HR (95% CI) for NRT
0.2 1 2 4
Lower with NRT
1.08 (0.56, 2.06)a
1.35 (1.03, 1.77)d
1.54 (1.08, 2.19)a
1.50 (1.14, 1.99)f
1.39 (1.09, 1.76)g
1.25 (0.92, 1.70)e
1.00 (0.34, 2.93)a
1.13 (0.57, 2.23)b
1.26 (0.63, 2.54)c
0.70 (0.30, 1.66)a
52 weeks
Figure 1 Forest plot of outcome results by 4 and 52 weeks.
Notes: aUnadjusted HR; bUnadjusted OR; cOR adjusted for lipid-regulating drugs (Y/N), CCI score (0/1-4/5+) and primary care consultations for IHD at baseline (Y/N); dHR 
adjusted for BMI (category included for missing status); eRR adjusted for CCI score (0/1-4/5+); fRR Adjusted for CCI score (0/1-4/5+), baseline primary care consultations 
for IHD (Y/N), and baseline primary care consultations for cerebrovascular disease (Y/N); gHR Adjusted for CCI score (0/1-4/5+) and number of primary care consultations 
(categorized 0-2/3-5/6-10/11+). Triangles, circles, and squares indicate odds ratio, hazard ratio, and rate ratio, respectively;
Abbreviations: IHD, ischemic heart disease; NRT, nicotine replacement therapy; OR, odds ratio; HR, hazard ratio; RR, rate ratio; CI, confidence interval; Consultations, 
consultations in primary/secondary care for IHD and cerebrovascular disease; advice, smoking cessation advice; Y/N, yes/no; CCI, Charlson Comorbidity Index; BMI, body 
mass index.
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compared with the current study, as well as looking only at 
outcomes up to 8 weeks of treatment. A second database study 
of 663 smokers with acute coronary syndrome that compared 
NRT versus no NRT reported no differences after 1 year for 
death, MI, repeat revascularization, or rehospitalization for 
angina, congestive heart failure, or arrhythmia.26 However, 
the authors acknowledge, as a limitation of the study, a lack in 
the number of patients needed to achieve 90% power, which 
could explain the difference in findings between that and 
the current study. This highlights the need for larger longer 
studies to evaluate the long-term effects of NRT.
An explanation for the differences in all-cause mortality 
between treatment groups in the current study could be pre-
scribing practices, with GPs preferentially prescribing NRT 
in patients with other smoking-related diseases, such as lung 
cancer. These patients could be more likely to be prescribed 
NRT, as this intervention has been shown to increase the 
likelihood of quitting by 50%–70%.10 An alternative expla-
nation is that the NRT cohort consisted of heavier smokers 
with a greater illness burden, who therefore had higher all-
cause mortality compared with those receiving advice only. 
However, this study was designed primarily to investigate the 
safety profile of NRT, and therefore treatment groups were not 
matched on other diseases. As such, we do not have cause of 
death information beyond that for IHD and cerebrovascular 
disease. Patients with other diseases were not excluded in 
order to include as wide a population as possible who were 
undertaking smoking cessation.
NRT is a widely used smoking cessation pharmacotherapy, 
owing to the low possibility of abuse and potential for depen-
dence.27 Bupropion sustained release was the first nonnicotine 
pharmacological treatment approved for smoking cessation.28 
Originally designed as an antidepressant in the US, it is the 
least prescribed smoking cessation treatment.11,13 There is 
evidence that bupropion is more effective than a placebo, but 
only weak evidence to suggest superiority over NRT.12 How-
ever, there is evidence of a potentially protective effect for the 
risk of major cardiovascular events with bupropion, although 
the reason for this is not well understood.20 Varenicline, a 
competitive nicotine receptor antagonist, has been available 
as a smoking cessation treatment since 2006.29 It has been 
suggested that varenicline may be more effective than NRT.29
Our study adds real-world data to the existing evidence 
from RCTs on the safety profile of NRT in patients with, 
or at a higher risk of, cardiovascular events. Our findings 
of increased cardiovascular events with NRT in high-risk 
patients indicate that further investigation is needed into 
both the safety of NRT and alternatives to NRT treatment in 
this group of smokers.
Strengths of the current study include the use of data 
on real-life patients from a large, high-quality source, the 
CPRD, which is well described and has previously been used 
in respiratory research.23 Furthermore, compared with many 
of the RCTs investigating NRT as a smoking cessation treat-
ment, this study has a larger patient population and longer 
follow-up period.
Limitations
The current study has a number of limitations. Firstly, 
there is lack of data on over-the-counter (OTC) purchases, 
particularly in light of the fact that most NRT in the UK 
is used without advice, and purchased OTC rather than by 
prescription.30 However, there is evidence that most patients 
who use OTC NRT do not exceed the recommended time of 
12 weeks,31 allowing us to infer that our secondary outcome 
period of 52 weeks is less likely to be affected by potential 
OTC use. On the other hand, the results indicate that the 
potential excess use of OTC NRT in the control group may 
be counteracting the observed difference between the groups. 
A further consideration is that patients taking NRT could 
potentially be exposed to elevated nicotine levels if they 
continue to smoke while taking NRT. However, owing to the 
flat dose–cardiovascular response relation for nicotine, the 
effects of cigarette smoking in addition to NRT are likely to be 
similar to those of smoking alone.32 Data on hospitalizations 
(emergency department attendance, inpatient admissions, 
and outpatient attendance) were limited because Hospital 
Episode Statistics–linked data were not available; as a result, 
hospitalizations were ascertained using information from GP 
records. There was no matching or adjustment for the severity 
of the smoker (cigarettes per day, pack years or Fagerstrom 
test), and thus, there is the potential that those in the NRT 
group were heavier smokers than those in the advice group. 
We did not analyze the time period of NRT use, and patients 
were only required to initiate on NRT to be included in the 
NRT group of the study. Our data did not provide information 
on the utilization of NRT, but only that it was prescribed, and 
we can only assume that NRT patients took the treatment as 
intended, making this an “intention to treat” analysis. We 
also lack information on details such as family history, a 
potentially influential factor as to whether a patient decides 
to seek cessation treatment with NRT. Furthermore, we do 
not know the rates of smoking cessation in each group; we 
can speculate that it was higher in the NRT group; however, 
this might not be the case. Compliance with NRT is likely 
to be higher in the prescription group as patients will have 
a clearer understanding of the benefit of the therapy owing 
to the advice of health care professionals. The Charlson 
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
28
-A
pr
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
238
Dollerup et al
comorbidity index (CCI) score was higher in the NRT group, 
which could lead us to assume that increased morbidity ini-
tially drove patients to seek treatment with NRT, and could 
therefore explain the worsened end points.
Confounding by indication may affect our results; GPs 
may assess patients with indications of poorer health, such as 
indicated by a high CCI score, or those with a higher risk of 
future poor outcomes, and prescribe NRT rather than advice. 
If higher risk patients were more likely to be given NRT, we 
may have overestimated the effect of NRT on outcomes. 
Confounding by indication is more of a concern in studies 
such as ours where initiators of treatment are compared 
with non-initiators as supported by Schneeweiss et al.33 A 
comparison between similar treatments would minimize this 
bias. The more similar the compared treatments are, the less 
potential there is for unmeasured confounding.
Matched analysis was conducted to achieve balance of 
covariates between the cohorts. Adjusted analysis was car-
ried out to minimize confounding. However, as we did not 
randomly assign patients to either NRT or advice, some bias 
may remain.
Both smoking and nicotine treatment have been found to 
increase heart rate and blood pressure.34–37 The hemodynamic 
effects of smoking have been linked to nicotine, with heart 
rate found to increase with intravenous nicotine, nicotine 
nasal sprays, and nicotine chewing gum.38–40 Nicotine was 
found to affect coronary artery constriction even at doses as 
low as 4 mg.41 These effects cause an increase in myocardial 
work and oxygen demand and result in impaired blood flow 
and oxygen supply to the heart. However, transdermal nico-
tine was found to have a lesser acute hemodynamic effect 
than smoking.42 Although there are not much data available 
on the effect of transdermal nicotine on coronary blood flow, 
Benowitz et al42 suggest that transdermal nicotine in smoking 
cessation treatment of patients with coronary heart disease 
is likely to be safer than cigarette smoking.
Further observational research is needed to provide 
insights into the effect of NRT on cardiovascular events. 
Data on nicotine exposure, which could be extracted through 
linked pharmacy and GP data, would be insightful. Extending 
the outcome period to longer than 1 year would increase the 
event numbers and allow a greater window to observe any 
potential associations. It would also be beneficial to obtain 
hospitalization data to ascertain whether increases in consul-
tation rates are limited to GP consultations or also applicable 
to hospitalizations. A sub-analysis by NRT product would add 
meaningful information in this space. Further investigation 
into the use of nonnicotine alternatives is needed. The pres-
ent study lacked the numbers to conduct such an analysis.
Conclusion
Although treatment with NRT during a short period (4 weeks) 
does not appear to have an impact on cardiovascular risks, a 
longer follow-up period of 52 weeks resulted in an increase in 
cardiovascular events for patients prescribed NRT, compared 
with those receiving smoking cessation advice only. In view 
of the ongoing global public health risk of cigarette smoking, 
there is an urgent need to investigate the safest treatments 
available for patients attempting smoking cessation.
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Supplementary material
Confounding factors
Owing to the potential for confounding demographic and comorbid factors, initial analysis identified key baseline confound-
ers, and the outcome analyses utilized appropriate statistical methods (logistical regression and matching), to minimize 
confounding.
Potential confounders examined at, or closest to, the index date were
•	 Age
•	 Sex
•	 Height
•	 Body mass index (BMI)
Potential confounders that were examined irrespective of when they occurred relative to the index date were confound-
ing diagnoses including
•	 Diabetes
•	 COPD
•	 Rhinitis
•	 Hypertension
•	 Cardiovascular disease
•	 Ischemic heart disease (IHD, subset of cardiovascular disease)
•	 Cerebrovascular disease (subset of cardiovascular disease)
•	 Angina (subset of IHD)
•	 Myocardial infarction (subset of IHD)
Other important unrelated comorbidities were expressed using the CCI. This was calculated on the basis of an algorithm 
of weighted Read code diagnosis codes in the year prior to the index date.
Potential confounders that were examined the year prior to the index date included cholesterol measurements
•	 Blood pressure
•	 Drug therapies
•	 General practice consultations
•	 Outpatient attendances
•	 Inpatient admissions
•	 Accident and emergency admissions
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Patient either receiving
NRT or smoking cessation
advice
Patients received bupoprion or
varencline
n = 3,695
Patient age <18 years or >75 years
n = 0
Not current smoker throughout
baseline period
n = 10,710
Patient not registered at practice
12 months prior to and after 
index smoking cessation attempt
n = 5,766
Patient switched to other
(pharmacological) interventions
during outcome period
n = 17,152
Total smoking patients
n = 95,243
NRT or smoking cessation advice patient
n = 91,548
Age 18 years to 75 years
n = 91,548
Current smoker
n = 80,838
Patient registered at practice
n = 75,072
Patient did not switch interventions
n = 57,920
Nicotine
replacement therapy
n = 17,121
Smoking cessation
advice
n = 40,799
Patient age 18–75 years
Current smoker throughout
baseline period
Patient registered at
practice 12 months prior to
and after index smoking
cessation attempt
Patient did not switch to
other (pharmacological)
interventions during
outcome period
Inclusion criteria
Exclusion criteria
Figure S1 Patient flow diagram for the unmatched NRT and smoking cessation advice cohorts.
Abbreviation: NRT, nicotine replacement therapy.
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Cardiovascular events following exposure to nicotine replacement therapy
Figure S2 Patient flow diagram for the matched NRT and smoking cessation advice cohorts.
Note: Advice refers to smoking cessation advice.
Abbreviation: NRT, nicotine replacement therapy.
Patients available
Same sex
Age ± 5 yrs
NRT = 17,121
NRT = 17,121
Advice = 40,799
Advice = 40,799
NRT patients (n = 0)
Advice patients (n = 0)
Lost on matching:
NRT patients (n = 0)
Advice patients (n = 0)
Lost on matching:
NRT patients (n = 0)
Advice patients (n = 0)
Lost on matching:
NRT patients (n = 0)
Advice patients (n = 0)
Lost on matching:
NRT patients (n = 0)
Advice patients (n = 2)
Lost on matching:
NRT patients (n = 2)
Advice patients (n = 15)
Lost on matching:
NRT patients (n = 3)
Advice patients (n = 31)
Lost on matching:
NRT patients (n = 10)
Advice patients (n = 37)
Lost on matching:
NRT patients (n = 383)
Advice patients (n = 7,323)
Total lost on matching:
NRT = 17,121
Hypertension
Cardiovascular
Diabetes
COPD
Ischemic heart disease
Cerebrovascular disease
Advice = 40,799
NRT = 17,121
Advice = 40,799
NRT = 17,121
Advice = 40,799
NRT = 17,121
Advice = 40,797
NRT = 17,119
Advice = 40,782
NRT = 17,116
Advice = 40,751
NRT = 17,106
Advice = 40,714
NRT/Advice 1:2 uniquely matched patients
Randomize
matching patients*
*Software used to randomly pick
unique matched patients NRT matched = 16,738Advice matched = 33,476
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